Literature DB >> 22161307

Immune mediated diseases and immune modulation in the neurocritical care unit.

Gloria von Geldern1, Thomas McPharlin, Kyra Becker.   

Abstract

This chapter will review the spectrum of immune-mediated diseases that affect the nervous system and may result in an admission to the neurological intensive care unit. Immunomodulatory strategies to treat acute exacerbations of neurological diseases caused by aberrant immune responses are discussed, but strategies for long-term immunosuppression are not presented. The recommendations for therapeutic intervention are based on a synthesis of the literature, and include recommendations by the Cochrane Collaborative, the American Academy of Neurology, and other key organizations. References from recent publications are provided for the disorders and therapies in which randomized clinical trials and large evidenced-based reviews do not exist. The chapter concludes with a brief review of the mechanisms of action, dosing, and side effects of commonly used immunosuppressive strategies in the neurocritical care unit.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22161307      PMCID: PMC3271148          DOI: 10.1007/s13311-011-0096-3

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  389 in total

Review 1.  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.

Authors: 
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

2.  Acute hemorrhagic leukoencephalitis with severe brainstem and spinal cord involvement: MRI features with neuropathological confirmation.

Authors:  Pedro S Pinto; Ricardo Taipa; Bruno Moreira; Carlos Correia; Manuel Melo-Pires
Journal:  J Magn Reson Imaging       Date:  2011-04       Impact factor: 4.813

3.  GABA(B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders.

Authors:  A Boronat; L Sabater; A Saiz; J Dalmau; F Graus
Journal:  Neurology       Date:  2011-03-01       Impact factor: 9.910

Review 4.  A systematic review of population based epidemiological studies in Myasthenia Gravis.

Authors:  Aisling S Carr; Chris R Cardwell; Peter O McCarron; John McConville
Journal:  BMC Neurol       Date:  2010-06-18       Impact factor: 2.474

5.  I.v. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barré syndrome.

Authors:  M K Sharief; D A Ingram; M Swash; E J Thompson
Journal:  Neurology       Date:  1999-06-10       Impact factor: 9.910

6.  Lambert-Eaton myasthenic syndrome presenting with severe respiratory failure.

Authors:  M W Nicolle; D J Stewart; H Remtulla; R Chen; C F Bolton
Journal:  Muscle Nerve       Date:  1996-10       Impact factor: 3.217

7.  Autoantibodies to glutamate receptor GluR3 in Rasmussen's encephalitis.

Authors:  S W Rogers; P I Andrews; L C Gahring; T Whisenand; K Cauley; B Crain; T E Hughes; S F Heinemann; J O McNamara
Journal:  Science       Date:  1994-07-29       Impact factor: 47.728

8.  Agrypnia excitata: clinical features and pathophysiological implications.

Authors:  Elio Lugaresi; Federica Provini
Journal:  Sleep Med Rev       Date:  2001-08       Impact factor: 11.609

9.  Obstructive hydrocephalus and progressive psychosis: rare presentations of neurosarcoidosis.

Authors:  Franklin D Westhout; Mark E Linskey
Journal:  Surg Neurol       Date:  2007-10-31

Review 10.  Multiple sclerosis: lessons from neuropathology.

Authors:  C F Lucchinetti; W Brueck; M Rodriguez; H Lassmann
Journal:  Semin Neurol       Date:  1998       Impact factor: 3.420

View more
  2 in total

Review 1.  Is dosing of therapeutic immunoglobulins optimal? A review of a three-decade long debate in europe.

Authors:  Jacqueline Kerr; Isabella Quinti; Martha Eibl; Helen Chapel; Peter J Späth; W A Carrock Sewell; Abdulgabar Salama; Ivo N van Schaik; Taco W Kuijpers; Hans-Hartmut Peter
Journal:  Front Immunol       Date:  2014-12-12       Impact factor: 7.561

2.  Imaging and clinical properties of inflammatory demyelinating pseudotumor in the spinal cord.

Authors:  Ying Wang; Min Wang; Hui Liang; Quntao Yu; Zhihui Yan; Min Kong
Journal:  Neural Regen Res       Date:  2013-09-15       Impact factor: 5.135

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.